AIM
BMRN icon

Acrospire Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Acrospire Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-400
Closed -$36K – 190
2017
Q2 		$36K Buy
400
+100
+33% +$9.1K 0.03% 1148
2017
Q1 		$26K Hold
300
– – 0.02% 1449
2016
Q4 		$25K Buy
300
+200
+200% +$17.2K 0.01% 1689
2016
Q3 		$9K Buy
+100
New +$9.42K 0.01% 1721

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acrospire Investment Management's BMRN Position: Q3 2017 in Review

Acrospire Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 400 shares — an estimated $36K sold.

Acrospire Investment Management first reported a position in BMRN in Q3 2016 and held it in 4 quarters. The position peaked at $36K in Q2 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • Acrospire Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 400 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $36K.
  • Acrospire Investment Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Acrospire Investment Management's BioMarin Pharmaceuticals position peaked at $36K in Q2 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.